Argent BioPharma Limited (ASX:RGT)
Australia · Delayed Price · Currency is AUD 0.0380
-0.0030 (-7.32%)
Aug 11, 2026, 3:56 PM AEST
Argent BioPharma Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 1.53 | 1.02 | 0.7 | 0.24 | 1.89 | 5.43 |
Cash & Short-Term Investments | 1.53 | 1.02 | 0.7 | 0.24 | 1.89 | 5.43 |
Cash Growth | 49.30% | 45.75% | 193.08% | -87.29% | -65.28% | 190.03% |
Accounts Receivable | 0.24 | 0.07 | 0.14 | 0.21 | 0.74 | 0.84 |
Other Receivables | - | 0.31 | 0.34 | 0.32 | 1.2 | 1.51 |
Receivables | 0.24 | 0.38 | 0.48 | 0.53 | 1.94 | 2.35 |
Inventory | - | 0.13 | 0.88 | 1.36 | 1.84 | 0.87 |
Prepaid Expenses | 0.12 | 0.5 | 0.69 | 0.4 | 0.8 | 0.55 |
Other Current Assets | - | - | - | - | - | 0.28 |
Total Current Assets | 1.89 | 2.03 | 2.74 | 2.53 | 6.46 | 9.48 |
Property, Plant & Equipment | 0.12 | 0.44 | 6.72 | 7.45 | 8.8 | 7.14 |
Long-Term Investments | - | - | 1.33 | - | 0.16 | 0.56 |
Goodwill | - | - | - | - | 3.15 | 7.05 |
Total Assets | 2.01 | 2.47 | 10.79 | 9.98 | 18.56 | 24.24 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 1.54 | 1.81 | 0.96 | 2.19 | 2.52 | 1.22 |
Accrued Expenses | - | 0.32 | 0.35 | 0.54 | 0.69 | 0.38 |
Short-Term Debt | 7.53 | 7.93 | 8.68 | 9.18 | 2.1 | 4.03 |
Current Portion of Leases | 0.01 | 0.11 | 0.22 | 0.19 | 0.28 | 0.21 |
Current Unearned Revenue | - | - | 0.55 | 0.66 | 1.81 | - |
Other Current Liabilities | - | 0.66 | 1.42 | 0.58 | 0.31 | 0.28 |
Total Current Liabilities | 9.09 | 10.83 | 12.18 | 13.33 | 7.71 | 6.13 |
Long-Term Leases | 0.06 | 0.25 | 0.82 | 0.38 | 1.97 | 1.77 |
Long-Term Unearned Revenue | - | - | 3.6 | 4.28 | 3.68 | 2.51 |
Other Long-Term Liabilities | 1.31 | 0.02 | 0.02 | 0.02 | 0.02 | - |
Total Liabilities | 10.46 | 11.1 | 16.61 | 18.02 | 13.38 | 10.41 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 139.62 | 138.59 | 123.29 | 103.69 | 97.25 | 84.51 |
Retained Earnings | -150.45 | -147.51 | -129.67 | -119.17 | -98.35 | -78 |
Comprehensive Income & Other | 2.38 | 0.3 | 1.23 | 8.08 | 6.93 | 7.32 |
Total Common Equity | -8.44 | -8.63 | -5.15 | -7.4 | 5.84 | 13.83 |
Minority Interest | - | - | -0.67 | -0.63 | -0.66 | -0.01 |
Shareholders' Equity | -8.44 | -8.63 | -5.82 | -8.03 | 5.18 | 13.83 |
Total Liabilities & Equity | 2.01 | 2.47 | 10.79 | 9.98 | 18.56 | 24.24 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | 7.6 | 8.29 | 9.72 | 9.75 | 4.35 | 6.02 |
Net Cash (Debt) | -6.07 | -7.26 | -9.02 | -9.51 | -2.47 | -0.58 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.09 | -0.13 | -0.24 | -3.23 | -0.96 | -0.31 |
Filing Date Shares Outstanding | 83.38 | 72.18 | 48.41 | 4.43 | 2.85 | 2.39 |
Total Common Shares Outstanding | 83.38 | 72.18 | 45.28 | 3.35 | 2.73 | 2.32 |
Working Capital | -7.2 | -8.8 | -9.44 | -10.8 | -1.25 | 3.35 |
Book Value Per Share | -0.10 | -0.12 | -0.11 | -2.21 | 2.14 | 5.96 |
Tangible Book Value | -8.44 | -8.63 | -5.15 | -7.4 | 2.69 | 6.79 |
Tangible Book Value Per Share | -0.10 | -0.12 | -0.11 | -2.21 | 0.99 | 2.93 |
Machinery | 0.14 | 0.95 | 9.79 | 10.04 | 9.07 | 1.94 |
Construction In Progress | - | - | - | - | - | 4.44 |